GLP-1 receptor agonists such as semaglutide (Ozempic®, Wegovy®, Rybelsus®) have significantly improved the management of obesity and type 2 diabetes, providing effective weight loss and cardiometabolic benefits. However, as their use becomes more widespread, there has been an increase in...